Recurrence of T1D in Pancreas Transplantation

胰腺移植中 T1D 复发

• 批准号: 7262512
• 负责人: George William Burke
• 金额: $ 29.84万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-01 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7262512
• 关键词: Amylases; Antigens; Appearance; Autoantibodies; Autoimmune Process; Autoimmunity; Avidity; B-Lymphocytes; Belief; Biological Assay; Biopsy; Bladder; Blood Cells; Cadaver; Chronic; Clinical; Data; Development; Diabetes Mellitus; Disease; Drainage procedure; End stage renal failure; Epitopes; Event; First Degree Relative; Frequencies; Future; Hyperglycemia; Immunology; Immunosuppression; Impairment; Infiltration; Insulin; Insulin-Dependent Diabetes Mellitus; Islet Cell; Islets of Langerhans; Islets of Langerhans Transplantation; Kidney; Kidney Transplantation; Knowledge; Laboratories; Learning; Literature; Lymphocyte; Measurement; Molecular; Monitor; Natural History; Onset of illness; Pancreas; Pancreas Transplantation; Pathology; Patients; Phenotype; Predictive Value; Principal Investigator; Prospective Studies; Range; Recurrence; Relative (related person); Reporting; Research; Research Personnel; Risk; Risk Factors; Role; Sampling; Screening procedure; Specificity; Testing; Therapeutic; Therapeutic immunosuppression; Time; Today; Transplant Recipients; Transplantation; Urine; autoreactive T cell; base; clinical application; clinically significant; cohort; experience; follow-up; functional status; graft function; immunosuppressed; insight; insulin secretion; islet; isoimmunity; peripheral blood; prevent; programs; prospective; research and development; response

DESCRIPTION (provided by applicant): Since 1990 we have performed over 275 simultaneous pancreas and kidney (SPK) transplants in patients with type 1 diabetes (T1D) and end-stage renal disease. We are presently following 225 recipients. While all patients became insulin-independent, 34 (15%) have returned to hyperglycemia after a mean follow-up of 5.7 years. Our preliminary data demonstrate the presence of diabetes-associated autoantibodies preceding the return of hyperglycemia in approximately 65% of the patients with hyperglycemia and in 40% of normoglycemic SPK recipients. The observed frequency of autoimmunity in association with increased risk of hyperglycemia is higher than previously reported in smaller and earlier studies. Patients with selective loss of insulin secretion and without evidence of rejection were studied in detail and were found to have the cardinal features of recurrence of autoimmunity, including autoantibodies, insulitis and the presence of autoreactive T cells in peripheral blood assessed by recently developed tetramer-based assays. Thus, our data provide evidence that recurrent autoimmunity is a clinical problem of great significance that was previously underestimated. We have assembled a team of investigators with experience in pancreas transplantation (Burke, Miami) and the immunology of T1D (Pugliese, Miami; Nepom, Seattle) to study the key immunological events associated with recurrence of autoimmunity in SPK recipients. We plan to (1) retrospectively and prospectively analyze our cohort of 225 SPK patients to determine the frequency and time course of autoantibody recurrence and the predictive value of autoantibodies for recurrence of disease; (2) prospectively follow pancreas transplant recipients and assess humoral and cellular responses on follow-up samples by: (a) monitoring autoantibody levels, (b) monitoring and phenotyping autoreactive T cells in peripheral blood, (c) assessing islet/pancreas pathology from biopsies performed in recipients with consistent recurrence of multiple autoantibodies and (d) monitoring and phenotyping autoreactive T cells from the pancreatic infiltrate obtained by pancreatic transplant explants and/or biopsies. The proposed studies will define the relationship between autoantibodies, autoreactive T cells, insulitis and insulin secretion in SPK recipients. Methodological advances such as tetramer-based assays offer an unprecedented opportunity to characterize epitope specificity, avidity and the functional status of autoreactive T cells and compare these parameters in cells from peripheral blood and the pancreatic infiltrate. These studies will provide critical information about the immunological mechanisms regulating recurrence of autoimmunity in SPK recipients and assess the predictive value of laboratory tests that may find clinical application in the pancreas transplant setting. The knowledge gained should also be relevant to islet cell transplantation and spontaneous disease.

描述（由申请人提供）：自1990年以来，我们已经在1型糖尿病（T1 D）和终末期肾病患者中进行了超过275例胰腺和肾脏（SPK）同时移植。我们目前正在跟踪225名接受者。虽然所有患者都成为胰岛素依赖型，但34例（15%）在平均随访5.7年后恢复高血糖。我们的初步数据表明，在约65%的高血糖患者和40%的血糖正常的SPK接受者中，在高血糖恢复之前存在糖尿病相关自身抗体。观察到的与高血糖风险增加相关的自身免疫频率高于先前在较小和早期研究中报告的频率。对选择性胰岛素分泌丧失和无排斥反应证据的患者进行了详细研究，发现其具有自身免疫复发的主要特征，包括自身抗体、胰岛炎和外周血中存在自身反应性T细胞，这些特征通过最近开发的基于四聚体的测定进行评估。因此，我们的数据提供的证据表明，复发性自身免疫是一个临床问题的重要意义，以前被低估。我们组建了一个具有胰腺移植（Burke，迈阿密）和T1 D免疫学（Pugliese，迈阿密; Nepom，西雅图）经验的研究团队，以研究SPK受体中与自身免疫复发相关的关键免疫学事件。我们计划（1）回顾性和前瞻性分析我们的225例SPK患者队列，以确定自身抗体复发的频率和时间进程以及自身抗体对疾病复发的预测价值;（2）前瞻性随访胰腺移植受者，并通过以下方式评估随访样本的体液和细胞反应：（a）监测自身抗体水平，（B）监测外周血中的自身反应性T细胞并对其进行表型分析，（c）从在具有多种自身抗体的一致复发的接受者中进行的活组织检查评估胰岛/胰腺病理学，以及监测和分型来自通过胰腺移植外植体和/或活组织检查获得的胰腺浸润物的自身反应性T细胞。这些研究将明确SPK受体中自身抗体、自身反应性T细胞、胰岛炎和胰岛素分泌之间的关系。方法学的进步，如基于四聚体的测定提供了一个前所未有的机会来表征表位特异性，亲合力和自身反应性T细胞的功能状态，并比较这些参数在外周血和胰腺浸润细胞。这些研究将提供关键信息的免疫机制调节复发的自身免疫性SPK受体和评估的预测价值的实验室检查，可能会发现在胰腺移植设置的临床应用。所获得的知识也应该与胰岛细胞移植和自发性疾病有关。